©Reuters. The biotech company Integra Therapeutics closes another round of 1.5 million
Barcelona, March 29 (.).- The biotech company Integra Therapeutics, which creates state-of-the-art gene writing tools, has closed an investment round of 1.5 million euros led by the venture capital manager Columbus Venture Partners.
This capital is added to the 4.5 million that Integra Therapeutics raised in December of last year with AdBio Partners, Invivo Capital and Takeda (T:) Ventures and thus completes its seed round, as planned.
Columbus’ investment has been made through its third fund, Columbus Life Science Fund III FCR, presented in 2021 and endowed with 120 million euros, and Damià Tormo, managing partner of the manager, will join the board of directors of Integra Therapeutics.
Integra Therapeutics has recently appointed Professor George Church, a pioneer in human genome editing, to the company’s scientific advisory board.
The company was founded in 2020 as a spin-off from Pompeu Fabra University (UPF) by Dr. Marc Güell and Dr. Ancia Sánchez-Mejías and is headquartered in the Barcelona Biomedical Research Park (PRBB).
It has the support of international investors (AdBio Partners, Columbus Venture Partners, Invivo Capital and Takeda Ventures) and organizations in the health and biomedical sector.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
